


Claims

1. A compound of formula I,



wherein

5 R¹ is halogen, and

R² is selected from the group consisting of

- i) heteroaryl, unsubstituted or substituted by 1 to 3 substituents individually selected from the group consisting of OH, halogen, cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy, halogen-C₁₋₆-alkyl, halogen-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl and hydroxy-C₁₋₆-alkyl;
- 10 ii) aryl, unsubstituted or substituted by 1 to 3 substituents individually selected from the group consisting of OH, halogen, cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy, halogen-C₁₋₆-alkyl, halogen-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl and hydroxy-C₁₋₆-alkyl;
- 15 iii) C₃₋₇-cycloalkyl, unsubstituted or substituted by 1 to 3 substituents individually selected from the group consisting of OH, halogen, cyano, C₁₋₆-alkyl, C₁₋₆-alkoxy, halogen-C₁₋₆-alkyl, halogen-C₁₋₆-alkoxy, C₁₋₆-alkoxy-C₁₋₆-alkyl and hydroxy-C₁₋₆-alkyl; and
- iv) C₁₋₆-alkyl, unsubstituted or substituted by 1 to 3 substituents individually selected from the group consisting of OH, halogen, cyano, C₁₋₆-alkoxy and halogen-C₁₋₆-alkoxy;

20 or pharmaceutically acceptable salts thereof,

wherein the term "heteroaryl", refers to an aromatic carbocyclic group having a single 4 to 8 membered ring or multiple condensed rings containing 6 to 14 ring atoms and containing 1, 2 or 3 heteroatoms individually selected from N, O and S, in which at least one heterocyclic ring is aromatic.

25 2. A compound according to claim 1, wherein R¹ is chloro.


3. A compound according to any of claims 1 or 2, wherein R² is selected from the group consisting of unsubstituted heteroaryl, unsubstituted aryl, unsubstituted C₃₋₇-cycloalkyl and unsubstituted C₁₋₆-alkyl.

4. A compound according to any of claims 1 to 3, wherein R² is selected from pyridinyl, pyrazinyl, phenyl, cyclopentyl, isopropyl and sec-butyl.
5. A compound according to any of claims 1 to 4, selected from the group consisting of

- 8-Chloro-1-(4-isopropoxy-cyclohexyl)-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene,
 1-(4-sec-Butoxy-cyclohexyl)-8-chloro-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene,
 8-Chloro-1-(4-cyclopentyloxy-cyclohexyl)-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene,
 8-Chloro-1-(4-phenoxy-cyclohexyl)-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene,
 5 8-Chloro-1-[4-(pyridin-2-yloxy)-cyclohexyl]-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene, and
 8-Chloro-1-[4-(pyrazin-2-yloxy)-cyclohexyl]-4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulene,

or pharmaceutically acceptable salts thereof.

6. A process for preparing a compound of formula I as defined in any of claims 1 to 5, which
 process comprises reacting a compound of formula II with a compound of formula III to a
 10 compound of formula I



wherein R¹ and R² are as defined in any of claims 1 to 4.

- ~~7. A compound of formula I according to any of claims 1 to 5, whenever prepared by a process~~
 15 ~~as defined in claim 6.~~

~~8.7.~~ A compound of formula I according to any of claims 1 to 5 for use as therapeutically active
 substance.

- ~~9.8.~~ A compound of formula I according to claims 1 to 5 for the use as therapeutically active
 substance for the therapeutic and/or prophylactic treatment of diseases and disorders which
 20 are associated with V1a receptor antagonism.

- ~~10.9.~~ A compound of formula I according to claims 1 to 5 for the use as therapeutically active
 substance acting peripherally and centrally in the conditions of dysmenorrhea, male or
 female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of
 vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive
 25 compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

~~11.10.~~ A pharmaceutical composition comprising a compound of formula I according to any of
 claims 1 to 5 and a pharmaceutically acceptable carrier and/or a pharmaceutically acceptable
 auxiliary substance.

~~12.~~11. Use of a compound of formula I according to any of claims 1 to 5 for the manufacture of a medicament for acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.

10 ~~13. A method for the use of a compound according to any of claims 1 to 5 acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior, which method comprises administering said compound of formula I to a human being or animal.~~